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Abstract
Background: In April 2009, a new pandemic strain of influenza infected thousands of persons in Mexico and the United
States and spread rapidly worldwide. During the ensuing summer months, cases ebbed in the Northern Hemisphere while
the Southern Hemisphere experienced a typical influenza season dominated by the novel strain. In the fall, a second wave of
pandemic H1N1 swept through the United States, peaking in most parts of the country by mid October and returning to
baseline levels by early December. The objective was to determine the seroprevalence of antibodies against the pandemic
2009 H1N1 influenza strain by decade of birth among Pittsburgh-area residents.
Methods and Findings: Anonymous blood samples were obtained from clinical laboratories and categorized by decade of
birth from 1920–2009. Using hemagglutination-inhibition assays, approximately 100 samples per decade (n = 846) were
tested from blood samples drawn on hospital and clinic patients in mid-November and early December 2009. Age specific
seroprevalences against pandemic H1N1 (A/California/7/2009) were measured and compared to seroprevalences against
H1N1 strains that had previously circulated in the population in 2007, 1957, and 1918. (A/Brisbane/59/2007, A/Denver/1/
1957, and A/South Carolina/1/1918). Stored serum samples from healthy, young adults from 2008 were used as a control
group (n = 100). Seroprevalences against pandemic 2009 H1N1 influenza varied by age group, with children age 10–19 years
having the highest seroprevalence (45%), and persons age 70–79 years having the lowest (5%). The baseline seroprevalence
among control samples from 18–24 year-olds was 6%. Overall seroprevalence against pandemic H1N1 across all age groups
was approximately 21%.
Conclusions: After the peak of the second wave of 2009 H1N1, HAI seroprevalence results suggest that 21% of persons in
the Pittsburgh area had become infected and developed immunity. Extrapolating to the entire US population, we estimate
that at least 63 million persons became infected in 2009. As was observed among clinical cases, this sero-epidemiological
study revealed highest infection rates among school-age children.
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Introduction
In April of 2009, a new pandemic strain of influenza infected
thousands of persons in Mexico and the United States and spread
rapidly throughout the globe [1]. During the summer period,
influenza occurred at low levels in the Northern Hemisphere,
whereas it dominated in the Southern Hemisphere [2]. In the fall,
a second wave of pandemic H1N1 swept through the United
States, peaking in most parts of the country by mid October and
returning to baseline levels by early December. In Allegheny
County (Pittsburgh), Pennsylvania the epidemic peaked in late
October (personal communication, Kirsten Waller, Pennsylvania
Department of Health, influenza surveillance data, 2009) in a
largely unvaccinated community. Estimates from Centers of
Disease Control and Prevention (CDC) suggested that by
December approximately 50 million people had been infected in
the United States, however the true number of infected cases could
not be measured with certainty due to a lack of serological
evidence of asymptomatic cases. The epidemiology of pandemic
H1N1 influenza appeared to be a mild to moderate disease
affecting school-age children preferentially over older adults with
elderly adults being underrepresented in severe cases [3,4]. As with
seasonal influenza, reporting of cases and hospitalizations
underestimates the true infection rates in the population [4].
Asymptomatic and mild cases are missed by current reporting
techniques and few studies have been performed to identify
seroprevalence during an epidemic. Although the pattern of
disease preponderance among the young has been described
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historically with prior pandemic influenza [5,6,7,8], characteriza-
tion of serologic differences among various age groups with respect
to various strains of influenza is lacking. This study aimed to
describe the community seroprevalence of antibodies to pandemic
H1N1 at the time of the peak of the second pandemic wave and to
characterize the existence of immunity to other historical strains of
H1N1 influenza. Measurement of the seroprevalence of H1N1
immunity provides valuable information about the likelihood of a
possible third wave and may be useful in decision-making about
immunization strategies.
Methods
Sample cohorts and collections
The samples analyzed were excess serum samples collected
anonymously from extra laboratory specimens from the University
of Pittsburgh Medical Center’s Presbyterian Hospital and the
Children’s Hospital of Pittsburgh from mid-November and early
December 2009. Pediatric samples were obtained from blood
samples collected in outpatient clinics during the week of
November 16, 2009. Adult samples (older than 20 years) were
obtained from the clinical laboratories of the UPMC hospitals
during the week of November 23, 2009. University of Pittsburgh
IRB approval [(exempt) #PRO09110164] was obtained. Blood
samples were collected using the honest broker system at the
University of Pittsburgh Laboratories and given to investigators
organized by decade of birth without other identifying informa-
tion. Each serum sample was classified by decade of birth of the
donor and tested in hemagglutination-inhibition assay (HAI)
against pandemic H1N1 (A/California/7/2009), a seasonal H1N1
(A/Brisbane/59/2007) and 1918 H1N1 (A/South Carolina/1/
1918). A subset of samples (50% from each decade) were tested
against and a historical H1N1 strain (A/Denver/1/1957)
corresponding to the last H1N1 circulating prior to the 1957
pandemic of H2N2. A set of serum samples (n = 100) collected
from young, healthy adults (average age 20.2+/21.3 years) in
2008, prior to the pandemic (pre-pandemic), was used as controls
for the assay. Reference sera from individuals vaccinated with
either inactivated trivalent seasonal Fluzone vaccine or pandemic
H1N1 FluMist (GSK) vaccines were used as positive controls.
Using population data from Allegheny County (United States
Census Bureau) [9], we extrapolated the number of people in each
age group who are likely to be immune to pandemic H1N1 at the
time of our study.
Generation of 1918 virus-like particles (VLPs)
HEK 293T cells (16107) (ATCC, Manassas, VA, USA) were
transfected using Lipofectamine2000 (Invitrogen) with 5 mg of
each plasmid DNA expressing A/South Carolina/1/1918 HA and
A/Brevig Mission/1/1918 NA; and also 10 micrograms of HIV-
1NL4-3 gag. Cells were incubated for 72 h at 37C and supernatants
containing VLPs were harvested. Supernatants were clarified by
low speed centrifugation at 10006g and sterile filtered using a 0.22
micron filter. VLPs were purified by centrifuging clarified
supernatant at 100,0006g through a 20% glycerol cushion and
resuspended in PBS. Total protein was quantified via BCA protein
assay (Pierce Chemical, Rockford, IL, USA) and VLPs were
aliquoted and stored at 280C.
Hemagglutination-inhibition (HAI) assays
Hemagglutination inhibition (HAI) assays were conducted as
previously described [10,11]. To inactivate non-specific inhibitors,
aliquots of each serum sample were separately treated with
receptor destroying enzyme (RDE) prior to being tested with a
final serum dilution of 1:10 (starting dilution for the assays).
Samples were serially diluted 2-fold into V-bottom 96-well
microtiter plates. An equal volume of virus, adjusted to
approximately 8HAunits/50 microliter was added to each well.
The plates were covered and incubated at room temperature for
30 min followed by the addition of freshly prepared 1% turkey
erythrocytes (RBCs) (Lampire Biologicals, Pipersville, PA, USA) in
Phosphate buffered saline (PBS). The plates were mixed by
agitation, covered, and allowed to set for 30 min at 25uC. The
HAI titer was determined by the reciprocal of the last dilution
which contained non-agglutinated RBCs. Positive and negative
serum controls were included on each plate. Samples with HAI
titers $1:40 were considered seropositive.
Phylogeny of Hemagglutinin
Sequences were aligned with MUSCLE 3.7 software and the
alignment was refined by Gblocks 0.91b software. Phylogeny was
determined using the maximum likelihood method with PhyML
software and bootstrap values represent 100 cycles. Trees were
rendered using TreeDyn 198.3 software [12]. The NCBI accession
numbers for the hemagglutinin (HA) sequences obtained through
the Influenza Virus Resource [13] and used in phylogeny
inference are as follows: ACP41105, A/California/04/2009;
ACP41953, A/California/7/2009; ACQ99613, A/Mexico/
4108/2009; ACA28844, A/Brisbane/59/2007; ABU50586, A/
Solomon Islands/3/2006; ACD37430, A/New Caledonia/20/
1999; ABD15258, A/Denver/1/1957; ABD77675, A/Puerto
Rico/8/1934; AAD17229, A/South Carolina/1/1918; and
AAD17219, A/New York/1/1918.
Sample Size Calculations
Sample size calculations performed based on an estimated
seroprevalence of 30% indicated that 89 samples would be
required per decade to detect seroprevalence +/210% within a
95% confidence interval.
Statistical analysis
Geometric mean HAI titers and standard error were calculated
for each group. Sensitivity analysis was conducted around HAI
titer cut offs of 1:40, 1:80 and 1:160 (data not shown) before the
decision was made to use the conventional 1:40 as the cut off value
for seropositivity. To describe the cross-reactivity between various
strains, Spearman’s correlation coefficients were calculated for
each antigenic pair by decade. Cochran-Armitage test for trend
was calculated across age groups. Chi square tests were used to
compare the difference in seropositivity between the seasonal and
novel H1N1 strains for each decade.
Results
Study population: 1920–2009
In November and early December 2009, approximately 2–4
weeks after the peak of the fall wave in Allegheny County
(Figure 1), serum samples were collected anonymously from 846
persons that ranged in age from 1 month to 90 years of age
(Table 1). Overall, ,21% of serum samples collected from all age
groups were positive for the pandemic H1N1 influenza strain, A/
California/7/2009. This is in contrast to pre-pandemic samples
from subjects in the 18–24 year-old age range, where only 6% of
sera collected in 2008 were HAI positive for pandemic H1N1
(Table 1), likely due to cross-reactivity. The percentage of persons
with serum that tested positive for pandemic H1N1 influenza (A/
California/7/2009) was highest among children in the 10–19 year
old age group (46%) and the 0–9 year-old age group (29%). The
Second Wave of H1N1 Influenza
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percentage of persons with serum that tested positive for HAI
antibodies against pandemic H1N1 was 21% or less among the
other age groups, with the lowest percentage of positive serum
samples among individuals between 70–79 year olds (Table 1 and
Figures 2 and 3). However, the percentage of samples positive for
pandemic H1N1 influenza was significantly higher in all age
groups (p,0.05), except the 70 year olds, compared to pre-
pandemic serum samples. The test for trend demonstrated
increasing seropositivity for both pandemic H1N1 among younger
cohorts (p = 0.001).
Each serum sample was also tested for HAI activity against the
seasonal H1N1 influenza strain, A/Brisbane/59/2007. This strain
was the World Health Organization recommended H1N1 strain
used by vaccine manufacturers for the past 3 influenza seasons
[14,15,16]. Nearly 50% of serum samples from children younger
than 20 years of age were positive for seasonal H1N1 and ,34%
of serum samples from individuals 20–29 years of age. For all other
age groups, 11–21% of serum samples were HAI positive for A/
Brisbane/59/2007 (Table 1). The test for trend showed increasing
seropositivity across the younger age groups (p,0.001). Serum
samples collected from individuals in the 0–9, 20–29, 70–79, and
80–89 year old age groups had statistically (p,0.05) different
percentage of positive samples against seasonal H1N1 influenza
than pandemic H1N1 influenza (Table 1). Samples from each age
group were also tested against historical strains of H1N1, A/
Denver/1/1957 and A/South Carolina/1/1918. The percentage
of samples positive for each of these strains by decade is described
in Table 1 and depicted in Figure 3.
To detect possible cross-reaction relationships between HAI
titers among influenza strains, correlation coefficients were
calculated for each decade and influenza strain tested. For each
decade, the antigenic pair of A/California/7/2009 and A/South
Carolina/1/1918 had stronger correlations than the antigenic pair
of A/California/7/2009 and A/Brisbane/59/2007 and the pair of
A/Brisbane/59/2007 and A/South Carolina/1/1918 except for
the 1930–1939 decade.
Figure 1. Allegheny County, Pennsylvania pandemic H1N1 cases. Sampling period for serosurvey (November 16-December 4, 2009) shown
relative to epidemic curve. Distribution of the novel H1N1 vaccine to health clinics began in late-November.
doi:10.1371/journal.pone.0011601.g001
Table 1. Percentage of blood samples positive for influenza antibody by decade of birth and by selected influenza strains.
Decade of Birth/age
range A/California/7/2009 A/Brisbane/59/2007 A/Denver/1/1957
A/South Carolina/1/
1918 n= p value^
2000s (0–9) 28% 47% 36% 2% 88 0.012
1990s (10–19) 45% 50% 44% 5% 96 0.470
1980s (20–29) 20% 39% 54% 13% 89 0.005
1970s (30–39) 14% 18% 17% 10% 81 0.392
1960s (40–49) 18% 19% 37% 14% 100 0.856
1950s (50–59) 22% 20% 58% 11% 96 0.858
1940s (60–69) 13% 21% 45% 13% 100 0.132
1930s (70–79) 5% 15% 50% 48% 100 0.018
1920s (80–89) 26% 11% 22% 59% 96 0.001
Pre-Pandemic Naı¨ve
(2008)
6% 22% 33 1% 100 0.001
*(HAI$1:40).
^ Chi square testing the difference in seropositivity between A/California/7/2009 and A/Brisbane/59/2007; p,0.05 is statistically significant.
doi:10.1371/journal.pone.0011601.t001
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We extrapolated the results from our sample to the local
population (Table 2). Thus, we estimate that 21.5% of the
population in Allegheny County is seropositive to the novel 2009
H1N1 influenza, including over 70,000 school-age children.
Extrapolating these results further to the entire US population,
we estimate that 63 million persons became infected in 2009.
Discussion
The emergence of a novel H1N1 strain challenged public health
officials and scientists to make prompt decisions about how best to
prevent transmission in the face of an imminent pandemic. The
need for more comprehensive serosurveys to understand infection
rates and population immunity has emerged as a significant tool
missing from our armamentarium. This study, which examined
real-time seroprevalence shortly after the fall wave (considered the
second pandemic wave) in the United States, contributes to our
understanding of the spread of the pandemic through the
population. It also sheds light on the hypothesis that prior
exposure to H1N1 influenza contributes to population immunity
against this novel strain and may explain some of the differential
distribution of affected age groups. A population based, prospec-
tive serologic study performed by the Health Protection Agency
(HPA) earlier this year in the UK contributed to the questions of
population immunity and incidence of this disease in distinct
groups in the United Kingdom (UK) [17]. While providing
information on incident cases, the UK study also highlighted
important geographic differences in spread of the disease even
within the same country and raised questions about the
mechanism for relative protection among the elderly. The UK
finding of 31% baseline seroprevalence among elderly (greater
than 80 years old)[17] suggests a cause for decreased infection in
this population and is supported by the findings of our study which
show high reaction to A/South Carolina/1/1918 among subjects
born in the 1920s with a high correlation between seropositivity to
the pandemic H1N1 and the 1918 strain. Using microneutraliza-
tion assays, a CDC evaluation of cross-protective antibodies
among prior seasonal influenza vaccinees demonstrated very low
pre-existing antibodies among the young with 33% cross-reactivity
among people over 60 years [18]. Similarly, a studies of stored
Figure 2. Percent seropositive (HAI$1:40) by decade of birth for A/California/7/2009; H1N1 influenza.
doi:10.1371/journal.pone.0011601.g002
Figure 3. Seropositive samples for historical influenza A H1N1 strains (A/Brisbane/59/2007, Denver/1/1957 and A/South Carolina/1/
1918).
doi:10.1371/journal.pone.0011601.g003
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serum samples from the pre-pandemic period found some level of
cross-reactive antibody in older adults [19] and that the oldest
individuals (born between 1909–1919; age 90–100) had antibodies
against the 2009 novel H1N1 influenza virus [20], consistent with
prior infection with 1918 influenza. In contrast, most individuals
born after 1944 lacked antibodies to the novel H1N1-like viruses.
The 1918-like influenza viruses and the 2009 novel H1N1-like
viruses are genetically related to the pandemic H1N1 strain
(Figure 4) through the classic swine influenza lineage [21,22] and
based on the three-dimensional structure of the HA molecule, the
antigenic epitopes of the novel 2009 H1N1 HA are more closely
related to those of the 1918-like influenza HA molecules than to
those of contemporary seasonal H1N1 influenza viruses [20].
Building on the work of Robert Shope in the 1930s [23],
Thomas Francis, Jr. coined the term ‘‘original antigenic sin’’ in
1955 [24,25] to describe the observation that the antibody
response to the first influenza infection of childhood remains the
dominant antibody response thoughout life. This hypothesis,
originally based on studies of human antibody response to various
strains of influenza viruses, was further supported by sequential
experimental infections in ferrets [26,27] and has been an
important concept in the understanding of influenza immunology
and a challenge for influenza vaccine development [28,29].
The patterns of antibodies against historical H1N1 strains seen
in this study (Figure 2) demonstrate expected age-specific
differences in prior influenza A infections based on known
circulation of H1N1 in the past century. In the elderly, the
combination of decreased disease pandemic influenza incidence,
the high levels of pre-existing antibodies against novel H1N1, and
our finding of the high seroprevalence of antibodies to the 1918
influenza strain, support the hypothesis of a role for the long
lasting immunologic memory of the initial influenza infection.
Correlations between the HAI antibody titers against 2009
pandemic H1N1 and the 1918 pandemic strain in individual sera
are also supportive. In contrast, seasonal H1N1 HAI results
showed only weak correlations with pandemic H1N1, especially
the 1957 Denver strain. The finding of 26% seroprevalence of
antibodies against 2009 pandemic H1N1 among those born in the
Table 2. Expected population prevalence of immunity to pandemic H1N1 following peak of Second Wave in Allegheny County,
PA.
Age Group Sero-positive A/California/7/2009 Population Estimate# Expected Number Sero-positive^
0–9 28% 150,446 42,130 (29416258938)
10–19 45% 164,409 73,984 (57116290836)
20–29 20% 152,510 30,502 (19415246256)
30–39 14% 180,840 25,318 (13183242353)
40–49 18% 203,977 36,716 (23029255482)
50–59 21% 146,770 30822 (19785244853)
60–69 13% 107,529 13,979 (7925223183)
70–79 5% 111,151 5,558 (2056213116)
80–89* 26% 64,014 16,644 (11394223173)
1,281,866 275,652 (2354422307215)
*Includes everyone over 85.
# Population estimates taken from US Census (2000).
^ Estimated range based on 95% confidence limits of proportion sero-positive.
doi:10.1371/journal.pone.0011601.t002
Figure 4. Genetic relatedness of HA from historical strains of influenza H1N1. The tree includes select H1N1 influenza isolates of the classic
swine and human influenza lineages (see Materials and Methods for database accession numbers). Phylogenetic trees were inferred from
hemagglutinin amino acid sequences using the maximum likelihood method. Bootstrap analysis values are shown above the branches. The scale bar
indicates the number of amino acid residue changes per unit length of the horizontal branches.
doi:10.1371/journal.pone.0011601.g004
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1920s may represent both cross-reactivity with the assay and
evidence for cross-protective immunity. The immunity afforded by
the presence of 57% seroprevalence of antibodies against the 1918
H1N1 could explain the lower incidence of pandemic H1N1
infection seen among the elderly in the pandemic thus far.
In school age children, intense social mixing patterns are known
to drive transmission of respiratory viruses, especially influenza
[30]. Our results suggest that absence of pre-existing immunity to
the new strain, especially from early historical H1N1 strains (1918,
1957), rendered children susceptible to the emerging virus, and
close socialcontact patterns further enhanced rapid spread of the
virus. The milder disease seen with this pandemic may also have
contributed to increased spread as more asymptomatic or
minimally symptomatic students continued to circulate among
their peers. Our results showing high seroprevalence of antibodies
against novel H1N1 (45%) and low cross reactive antibodies
against the most highly genetically related 1918 strain (5%) among
children 10–20 years old are supportive of both immune-related
and contact-related susceptibility. Further support of the role of
social mixing in the disease spread comes from more detailed sub-
analysis of the age-specific immunity pattens of the children less
than 10 years old. Those in the school age group (5–9 year olds)
were 50% positive, while very few samples from those less than 5
years old were positive (data not shown). Further work to correlate
epidemiologic data and immunologic responses to hemagglutinin
from different interpandemic periods should be done.
Production of a timely study that was consistent with US privacy
regulations in the setting of a rapidly evolving pandemic proved
difficult, and we faced several limitations. Because we used
anonymous laboratory specimens, clinical information such as
history of influenza-like illness, or vaccination status was
unavailable. However, the timing of the sampling relative to
vaccine availability in Pittsburgh suggests that these samples are
likely from a largely unvaccinated population during the peak of
the second pandemic wave. While the pediatric samples were
mostly outpatient samples, the adult samples arise from a
hospitalized cohort and therefore may under-represent true
seropositivity among community dwelling healthy adults who
might be expected to engage in more social mixing than
hospitalized adults. This would be especially true of the young,
working age adults in their 30s to 50s (decades of birth 1960s and
1970s). However, given the similarity between these results and
published epidemiology of the pandemic thus far, the sample
appears to be fairly representative of what has been seen
throughout the globe. It is important to note that samples were
collected approximately 2–3 weeks after the pandemic peak
implying that seroprevalence in all age groups is likely to be higher
at this point in time, allowing for further seroconversion from both
natural infection and vaccination. Finally, the specimens were a
convenience sample from excess blood at participating clinical
laboratories, and not a true random sampling of the population.
Conclusion
The novel 2009 H1N1 influenza strain has been found to have a
relatively low transmissibility, i.e. an R0 [31,32] of 1.3. Our finding
of high anti-2009 H1N1seroprevalences among school children
and high anti-1918 H1N1 seroprevalences among the elderly
suggest that further viral transmission is not likely. With current
estimates of seroprevalence and continued increases in population
due to vaccination, a significant change in viral antigens or a
change in population immunity would be required for further
disease spread. However, we cannot rule out the possibility that
geographical pockets of limited immunity may be present in which
a third wave may yet occur. Ongoing viral and serosurveillance
efforts will be essential to inform decisions around vaccination and
other disease mitigating strategies.
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